|
|
|
| Efficacy of Letrozole Combined with Recombinant Human Growth Hormone in the Treatment of Adolescent Short Stature Boys and Drug Effects on Physical Development and Bone Metabolism |
| FU Chengli, NIU Wanke |
| Nanyang Zhang Zhongjing Hospital,Nanyang Henan 473000 |
|
|
|
|
Abstract 【Objective】To study the efficacy of letrozole combined with recombinant human growth hormone in treating boys with pubertal short stature and drug effects on physical development and bone metabolism.【Methods】One hundred and fifty boys with adolescent short stature disorder admitted to the hospital from January 2021 to January 2022 were divided into a control group and a combination group with 75 cases each by the random number table method. The control group was treated with recombinant human growth hormone and the combination group was treated with letrozole combined with recombinant human growth hormone. The physical development indexes [height,weight,growth velocity (GV),height standard deviation score (HtSDS)],serum bone metabolism indexes [osteocalcin (OC),bone alkaline phosphatase (BALP),pre-collagen type Ⅰ amino-terminal peptide (PINP),β-collagen degradation product (β-CTX)],serum appetite stimulating hormone (Ghrelin),serum insulin-like growth factor binding protein-3 (IGFBP-3) levels,core generalized children's quality of life scale (PedsQL) scores,and incidence of adverse reactions were compared between the two groups.【Results】The physical development indexes in the combined group were higher than those in the control group after 6 and 12 months of treatment (P<0.05). After 6 and 12 months of treatment,the improvement of serum bone metabolism indexes and levels of both serum Ghrelin and IGFBP-3 in the combined group were greater than those in the control group (P<0.05). The PedsQL score in the combined group was higher than that in the control group after 6 and 12 months of treatment (P<0.05 ). The overall incidence of adverse reactions in the combined group was 9.33% and overall incidence of adverse reactions was 6.67% in the control group,which was not statistically significant (P>0.05).【Conclusion】The combination of letrozole and recombinant human growth hormone is effective in treating male children with adolescent short stature disorder,and it can regulate the level of bone metabolic indexes and promote the growth and development of children with high safety.
|
|
Received: 06 April 2023
|
|
|
|
|
|
[1] 陈立娟,李斌,杨丽昕,等.赖氨酸磷酸氢钙颗粒联合重组人生长激素对矮小症患儿生长发育的影响[J].儿科药学杂志,2022,28(1):41-45.
[2] 步佳霖,温丙友,姚玲.重组人生长激素联合心理干预治疗特发性矮小症患儿的疗效及机制研究[J].中国现代医学杂志,2021,31(20):91-96.
[3] 张蔷,刘丽君,李金英,等.来曲唑改善青春期特发性矮小症男童身高的疗效观察[J].实用医学杂志,2021,37(3):369-373.
[4] 袁红虹,韩雯雯,王静静.大剂量重组人生长激素治疗对矮小症患儿生长发育相关指标的影响[J].临床误诊误治,2021,34(12):104-107.
[5] 雷巧容,李自尊,宋芬芳,等.生长激素释放肽基因多态性与青春期前特发矮小患儿重组人生长激素治疗疗效的关系研究[J].实用医院临床杂志,2022,19(6):143-147.
[6] 马梦瑾,罗臻臻,李志洁.重组人生长激素治疗特发性矮小症对患儿血清p21 waf/cip1、瘦素水平及生长情况的影响[J].中华生物医学工程杂志,2021,27(3):311-314.
[7] 杨珂,穆颖.芳香化酶抑制剂在男科疾病治疗中的临床应用[J].中国男科学杂志,2021,35(5):83-86.
[8] 乔玉.青春期大骨龄矮身材儿童治疗方案的真实世界研究[D].山东:山东大学,2021.
[9] 郑一波,徐金亮.基因重组人生长激素治疗不同年龄矮小症的效果及对骨代谢、胰岛素样生长因子-1、维生素D3的影响[J].中国基层医药,2021,28(4):500-503.
[10] 石星磊.辨证论治联合重组人生长激素治疗矮小症临床研究[J].新中医,2021,53(1):98-100.
[11] 黄占克,刘怡闻,李维丽,等.赖氨酸磷酸氢钙颗粒联合重组人生长激素治疗儿童特发性矮小症的临床研究[J].现代药物与临床,2021,36(6):1203-1206.
[12] 肖青凤,吴琰,史晓宁,等.不同剂量重组人生长激素治疗对特发性矮小症患儿骨代谢、甲状腺功能和血清Ghrelin、IGF-1水平的影响[J].现代生物医学进展,2021,21(23):4569-4572.
[13] 吴丽琴,赵明,傅乐乐,等.开胃健脾贴对特发性矮小症患儿生长及血清IGFBP-3、IGF-1水平的影响[J].中国中医药科技,2021,28(2):191-193. |
|
|
|
2023, Vol. 40 
